HCC 1937 人乳腺癌细胞

CRL-2336 HCC 1937 人乳腺癌细胞，原代细胞|细胞系|细胞株|菌种原代细胞、细胞系。细胞库管理规范，提供的细胞株背景清楚，提供参考文献和最优培养条件！

CRL-2336 HCC 1937 人乳腺癌细胞 的详细介绍

CRL-2336 HCC 1937 人乳腺癌细胞

ATCC® Number: CRL-2336™
Designations: HCC1937
Depositors: AF Gazdar, AK Virmani
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent, The line grows as large epithelial cells with a tendency to float at high cell densities
Organism: Homo sapiens (human)
Morphology: epithelial

Source: Organ: mammary gland; breast
Tissue: duct
Tumor Stage: TNM stage IIB, grade 3
Disease: primary ductal carcinoma
Cellular Products: Epithelial glycoprotein 2 (EGP2)
cytokeratin 19
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Isolation: Isolation date: October 13, 1995
Receptors: estrogen receptor, negative
progesterone receptor, negative
Oncogene: BRCA1 (mutated, insertion C at nucleotide 5382), her2/neu -, p53 -
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 13
D16S539: 13,14
D5S818: 12
D7S820: 9,10
THO1: 6
TPOX: 11
vWA: 16,17
Cytogenetic Analysis: CRL-2336 is highly transformed which is evident from the chromosome count and karyotype description. The modal chromosome number is 100. At least forty-three marker chromosomes, involving nearly every chromosome, were found. Chromosome 1 and chromosome 3 derivative chromosomes were verified using commercial whole chromosome paint (fluorescent in-situ hybridization (FISH)) probes. An acrocentric chromosome with an extra C-band at qter was detected (2 copies per metaphase). There were no normal X chromosomes however at least one derivative X was seen in each cell. The absence of a Y chromosome was verified by QM staining and C-bands. Normal copies of N1, N4, N15, N16 and N18 were absent. More detailed cytogenetic information is available upon request.
Age: 23 years adult
Gender: female
Ethnicity: Caucasian
Comments: This cell line was initiated from a primary ductal carcinoma on October 13, 1995, and took 11.5 months to establish
The tumor was classified as TNM Stage IIB, grade 3
BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation
This mutation was present in two other family members; an identical sister also developed breast cancer
The cell line has an acquired mutation of TP53 with wild-type allele loss; an acquired homozygous deletion of the PTEN gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer
The cells are negative for expression of Her2-neu and for expression of p53.
HCC1937 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19
The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR)
An EBV transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
normal (or near-normal) cell line established from the same patient:ATCC CRL-2337
purified DNA:ATCC CRL-2336D
purified RNA:ATCC CRL-2336R
cell pellet:ATCC CRL-2336P
References: 34277: Tomlinson GE, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation. Cancer Res. 58: 3237-3242, 1998. PubMed: 9699648
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
Related Links
NCBI Entrez Search
Make a Deposit
Frequently Asked Questions
Material Transfer Agreement
Technical Support
Related Cell Culture Products